The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models

Cardiovascular Research

Volumn 99, Issue 4, 2013, Pages 716-723

  Heinonen, Suvi E ^a   Kivelä, Annukka M ^a   Huusko, Jenni ^a   Dijkstra, Marike H ^a   Gurzeler, Erika ^a   Mäkinen, Petri I ^a   Leppänen, Pia ^a   Olkkonen, Vesa M ^b   Eriksson, Ulf ^c   Jauhiainen, Matti ^d   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Atherosclerosis; Gene therapy; Genetically altered mice; Lipoprotein lipase; Vascular endothelial growth factor

Indexed keywords

LIPOPROTEIN LIPASE; MESSENGER RNA; TRIACYLGLYCEROL; VASCULOTROPIN A;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THORACIC AORTA; VIRAL GENE DELIVERY SYSTEM;

ATHEROSCLEROSIS; GENE THERAPY; GENETICALLY ALTERED MICE; LIPOPROTEIN LIPASE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, LDL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883225647     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt148     Document Type: Article

References (27)

1. Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007;49:1015-1026.
2. Moreno PR, Purushothaman KR, Zias E, Sanz J, Fuster V. Neovascularization in human atherosclerosis. Curr Mol Med 2006;6:457-477.
3. Moulton KS, Heller E, Konerding MA, Flynn E, PalinskiW, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-1732.
4. Drinane M, Mollmark J, Zagorchev L, Moodie K, Sun B, Hall A et al. The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res 2009;104:337-345.
5. Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNAvaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:1095-1100.
6. Celletti FL,Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7: 425-429.
7. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001;37:2126-2130.
8. Leppanen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U et al. Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 2005;112:1347-1352.
9. GreeveJ, Altkemper I, Dieterich J, Greten H, Windler E. Apolipoprotein BmRNAediting in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 1993;34:1367-1383.
10. Hogarth CA, Roy A, Ebert DL. Genomic evidence for the absence of a functional cholesteryl ester transfer protein gene in mice and rats. Comp Biochem Physiol B Biochem Mol Biol 2003;135:219-229.
11. Yan D, Jauhiainen M, Hildebrand RB, Willems van Dijk K, Van Berkel TJC, EhnholmCet al. Expression of human OSBP-related protein 1L in macrophages enhances atherosclerotic lesion development in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:1618-1624.
12. Ehnholm C, Kuusi T. Preparation, characterization, and measurement of hepatic lipase. Methods Enzymol 1986;129:716-738.
13. KhovidhunkitW, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-1196.
14. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity.AmJ Physiol Endocrinol Metab 2009;297:E271-E288.
15. Kivelä AM, Dijkstra MH, Heinonen SE, Gurzeler E, Jauhiainen S, Levonen A-L et al. Regulation of endothelial lipase and systemic HDL cholesterol levels by SREBPs and VEGF-A. Atherosclerosis 2012;225:335-340.
16. Rensen P, Herijgers N, Netscher M, Meskers S, van Eck M, van Berkel T. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 1997;38: 1070-1084.
17. Dichek HL, Johnson SM, Akeefe H, Lo GT, Sage E, Yap CE et al. Hepatic lipase overexpression lowers remnant and HDL levels by a noncatalytic mechanism in LDL receptordeficient mice. J Lipid Res 2001;42:201-210.
18. Dichek HL, Qian K, Agrawal N. The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient 'apoB-48-only' and 'apoB-100-only' mice. J Lipid Res 2004;45:551-560.
19. Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D et al. Lipoprotein clearance mechanisms in LDL receptor-deficient 'Apo-B48-only' and 'Apo-B100-only' mice. J Clin Invest 1998;102:1559-1568.
20. Niemeier A, Gafvels M, Heeren J, Meyer N, Angelin B, Beisiegel U. VLDL Receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res 1996;37:1733-1742.
21. Hu L, van der Hoogt CC, Espirito Santo SM, Out R, Kypreos KE, van Vlijmen BJ et al. The hepatic uptake of VLDL in lrp-ldlr-/-vldlr-/-mice is regulated by LPL activity and involves proteoglycans and SR-BI. J Lipid Res 2008;49:1553-1561.
22. Cerne D, Melkic E, Trost Z, Sok M, Marc J. Lipoprotein lipase activity and gene expression in lung cancer and in adjacent noncancer lung tissue. Exp Lung Res 2007;33:217-225.
23. Kö ster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of Angptl4 and Angptl3: regulation of triglyceride metabolism. Endocrinology 2005;146:4943-4950.
24. Ooi EM, Russell BS, Olson E, Sun SZ, Diffenderfer MR, Lichtenstein AH et al. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations. Arterioscler Thromb Vasc Biol 2012;32:459-466.
25. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997;96:1737-1744.
26. Avraham-Davidi I, Ely Y, Pham VN, Castranova D, Grunspan M, MalkinsonGet al. ApoBcontaining lipoproteins regulate angiogenesis by modulating expression of VEGF receptor. Nat Med 2012;18:967-973.
27. Stathopoulou MG, Bonnefond A, Ndiaye NC, Azimi-Nezhad M, El Shamieh S, Saleh A et al. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J Lipid Res 2013;54:535-541.